The MYD88 L265P mutation has been shown to be a gain of function driver mutation in models such as ABC non-Hodgkin lymphoma cell lines, while activated MYD88 induces NF-kappa B signaling.[6,7]. Here, MYD88 is linked to aneurysmal bone cyst.